Introduction: Demographic and medical factors influencing AID AM use were evaluated to better understand inequities in glycemic outcomes among youth with T1D.
Methods: Retrospective chart review was conducted for 74 youth with T1D who started AID between 12/1/2022 to 5/31/2023 to examine time spent in AM 0-3 and 3-6 months after AID initiation. Mixed effects models assessed age, T1D duration, sex, race/ethnicity, insurance, AID system and input, and CGM metrics’ impact on time spent in AM. X2 and Mann Whitney U tests assessed for differences between youth with optimal (<u>></u>90%) and suboptimal (<90%) time spent in AM.
Results: Demographic and glycemic characteristics are described in Table 1. Race/ethnicity differed significantly among optimal and suboptimal AID use with NHB youth more likely to have suboptimal use (3mo p<.05, 6mo<0.001). Youth with optimal AID use had better glycemic outcomes at 3 and 6 months versus suboptimal use. Mixed effects models demonstrated that AID system type (p<.05) was predictive of optimal AM use at 3 months. Younger age at pump start, longer duration of T1D, more boluses/day, and higher % CGM wear time (all p’s <.05) were associated with higher AID use at 6 months.
Conclusions: Youth with optimal AID use had significantly better glycemic outcomes. Efforts to address individual level AID use and barriers can help to promote optimal AM use and improve health outcomes for all youth living with T1D.
J. Grundman: Research Support; Dexcom, Inc. R.L. Longendyke: None. A.G. Perkins: Research Support; Tandem Diabetes Care, Inc., Dexcom, Inc. M. Monaghan: Employee; National Institute of Diabetes and Digestive and Kidney Diseases. R. Streisand: None. S. Majidi: Other Relationship; Sanofi.
